Image Ben Hargreaves R&D Mpox is on the rise again as outbreak gathers pace The original mpox outbreak began in 2022, but case numbers have rumbled on, despite countermeasures. Market Access Drug pricing overhaul sparks tension with industry Up until recently, political rhetoric targeting the pharma industry had been largely all bark and no bite. R&D Drug repositioning to bring forgotten assets from shelves to... A problem very rarely spoken about is the treatments that are promising, but are not developed further. Patients Power to the patients: Patient organisations enabling drug d... Drug development is a complex process and there are many stakeholders involved in bringing treatments to patients. Load more results
R&D Mpox is on the rise again as outbreak gathers pace The original mpox outbreak began in 2022, but case numbers have rumbled on, despite countermeasures.
Market Access Drug pricing overhaul sparks tension with industry Up until recently, political rhetoric targeting the pharma industry had been largely all bark and no bite.
R&D Drug repositioning to bring forgotten assets from shelves to... A problem very rarely spoken about is the treatments that are promising, but are not developed further.
Patients Power to the patients: Patient organisations enabling drug d... Drug development is a complex process and there are many stakeholders involved in bringing treatments to patients.
News Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer Eli Lilly's imlunestrant (Inluriyo) for breast cancer has received a new FDA approval, in combination with CDK4/6 inhibitor abemaciclib (Verzenio).
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
